Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

What Was Tested

In this phase 3 trial, researchers set out to test Semaglutide for fat loss, obesity & body recomposition.

It had two arms (groups): Semaglutide (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

The registry lists 450 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. Female or male (sex at birth). Age 18 years or above at the time of signing the informed consent. Body mass index (BMI) of. ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.

The full record lists 7 inclusion and 3 exclusion criteria.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

The fat loss, obesity & body recomposition participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Groups ran in parallel: each of the fat loss, obesity & body recomposition participants stayed in one arm throughout.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-08-12 with completion listed for 2028-02-22.

It ran at 62 sites in United States (16), Poland (9), Spain (8), Bulgaria (6), Belgium (5) and Greece (5).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Relative change in body weight (time frame: From baseline (week 0) to week 60).

It also tracked 22 secondary outcomes, for example Change in waist circumference, Change in body weight, Change in high sensitivity C-Reactive Protein (hsCRP), Change in systolic blood pressure, Change in diastolic blood pressure and Change in fasting plasma glucose (FPG).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 450 people with fat loss, obesity & body recomposition.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.